Even if CXCR1/2 inhibition therapies are really promising for treating various disorders, it would be crucial for future clinical applications to evaluate the possible unwanted side effects, such as neutropenia, increased risk infections and gastrointestinal problems. The gene discussed is CXCR1; the disease is neutropenia.